Novelix Pharmaceuticals, Inc. (Novelix), a Delaware corporation, is a private, La Jolla based, biotechnology company committed to developing innovative, proprietary, dermatology products with large market potential to treat serious skin diseases. The company’s main focus is the development of NVX-207, a novel, topical drug candidate with the potential to change how actinic keratosis (AK), basal cell carcinoma and genital warts are treated. Current treatment options for each of these indications have significant inflammatory side effects, are often painful, suffer from high recurrence rates and/or poor cosmetic outcomes. The medical treatment costs for each of these indications exceeds US$1billion in the US alone (total medical costs 2004-US$4.2 billion).
Beyond its innovative compounds with strong IP positions (over 30 composition of matter patents have issued) and its experienced team, the company differentiates itself through its business model. Novelix is a “virtual company plus”. Novelix operates as a virtual company with a very low monthly burn. Plus, Novelix also leverages its many personal connections at top quality institutions so that with little or no cash outlay by the company, drug development and experimentation conducted by quality personnel at state-of-the-art facilities provide mission critical data and enhance our intellectual property value. The company further reduces risk by evaluating its drug candidates, not only in commonly used model systems, but also, in canine patients with spontaneously occurring diseases that more closely resemble conditions seen in humans. Recently, Novelix successfully completed a human pilot with one of its lead drug candidates.
Novelix has selected the NVX-207 program for further development.